Top 10 U.S. Drugs for 2012 First Quarter

Health and Healthcare

Published: July 18, 2012 10:56 am

Last Updated: July 18, 2012 10:57 am

Online drug research firm drugs.com today released its list of the top 100 selling drugs in the United States for the first quarter of 2012. The top five sellers include drugs from Bristol-Myers Squibb Co. (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Merck & Co. (NYSE: MRK) and Japan’s Otsuka Pharmaceutical Co. In addition, GlaxoSmithKline (NYSE: GSK), Eli Lilly & Co. (NYSE: LLY) and Abbott Laboratories (NYSE: ABT) were among the top 10 sellers.

The list:

Plavix (BMY) — $1.62 billion in sales
Nexium (AZN) — $1.40 billion
Ability (Otsuka) — $1.34 billion
Singulair (MRK) — $1.24 billion
Seroquel (AZN) — $1.16 billion
Advair Diskus (GSK) — $1.14 billion
Crestor (AZN) — $1.12 billion
Cymbalta (LLY) — $1.03 billion
atorvastatin (generic) — $0.95 billion
Humira (ABT) — $0.93 billion

The biggest gain compared to the fourth quarter of 2011 went to the atorvastatin generic, which saw sales rise by nearly $450,000. The generic has drawn sales from Lipitor, made by Pfizer Inc. (NYSE: PFE), which lost patent protection last year. Lipitor sales fell by more than $760,000 in the quarter to just over $840,000.

A generic version of Plavix — clopidogrel — recently hit the market, so the top of the rankings may be in for a change later this year.

Paul Ausick

Travel Cards Are Getting Too Good To Ignore (sponsored)

Credit card companies are pulling out all the stops, with the issuers are offering insane travel rewards and perks.

We’re talking huge sign-up bonuses, points on every purchase, and benefits like lounge access, travel credits, and free hotel nights. For travelers, these rewards can add up to thousands of dollars in flights, upgrades, and luxury experiences every year.

It’s like getting paid to travel — and it’s available to qualified borrowers who know where to look.

We’ve rounded up some of the best travel credit cards on the market. Click here to see the list. Don’t miss these offers — they won’t be this good forever.